Additional Information
Level of instruction: Intermediate
Intended audience: This course is intended for histology bench technicians and technologists, supervisors, and administrators.
Author information: Joelle Weaver MAOM, HTL(ASCP), QIHC is a certified histotechnologist with a broad range of practical histology experience within the clinical histopathology setting. She has received qualification in immunohistochemistry (IHC) from the American Society for Clinical Pathology and Green Belt certification from Purdue University, West Lafayette, Indiana. Joelle's bachelor's degree was received from Bowling Green State University in Bowling Green, Ohio and her Master's Degree was awarded from Bluffton University in Bluffton, Ohio. She is a graduate of a NAACLS accredited histotechnology program and has held positions as adjunct professor, education coordinator, and program director at Columbus State Community College in Columbus Ohio (2002-2011). Joelle currently works as a histotechnologist and technical consultant in Louisville, Kentucky, specializing in IHC.
Reviewer information: Carla J. Shoffeitt, MSM, HT(ASCP) is the Manager of the Pathology Department of Emory St. Joseph’s Hospital of Emory Healthcare in Atlanta, Georgia. She holds a Master of Science Degree in Healthcare Management as well as a Bachelor of Science degree in Biology from Troy University, Troy, Alabama. She is certified as a Histotechnician and has 25 years of experience in the field of Histology.
Course description: Toxicity, side effects, and unpredictable effectiveness have been the hallmark of anti-cancer therapies used in the past to treat breast and other primary cancers. Targeted therapies have been developed which reduce patient risk and provide remarkable improvement in patient outcomes. This course will discuss how predictive markers/testing are used to select patients who are most likely to respond positively to a specific breast cancer treatment, including current testing methodologies and compliance standards.